Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914602 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
A Phase 1 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00914602: Completed Phase 1 study, sponsored by XenoPort.
NCT00914602 is a Phase 1 study that has completed, run by XenoPort. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914602, a Phase 1 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation \[administered with Lodosyn® (carbidopa)\] and Sinemet® tablets in subjects with Parkinson's disease with Motor Fluctuations.
Primary Outcome
To establish a pharmacokinetic profile for XP21279
Interventions
- DRUG Sinemet 25-100 Oral Tablet
- DRUG XP21279
- DRUG Carbidopa Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00914602 record still lists
NCT00914602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Sinemet 25-100 Oral Tablet is the first listed.
NCT00914602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00914602 about?
NCT00914602 is a clinical study titled "An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects". The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation \[administered with Lodosyn® (carbidopa)\] and Sinemet® tablets in subjects with Parkinson's disease with Motor Fluctuations.
What is the current status of trial NCT00914602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00914602?
The interventions under investigation include: Sinemet 25-100 Oral Tablet (DRUG), XP21279 (DRUG), Carbidopa Pill (DRUG).
Who is sponsoring clinical trial NCT00914602?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00914602's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia